Approved Treatments for COVID-19

Name
Approved Treatments for COVID-19
Accession Number
DBCAT005187
Description

Treatments that have been approved for the indication of treating COVID-19 infections

Drugs
DrugDrug Description
RemdesivirA nucleoside analog used to treat RNA virus infections including COVID-19.
RegdanvimabA monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19.
CasirivimabPart of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
ImdevimabPart of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
BebtelovimabA human IgG1κ monoclonal antibody targeted against the spike protein of SARS-CoV-2 which is used in the treatment of mild-to-moderate COVID-19.
Drugs & Drug Targets
DrugTargetType
RemdesivirReplicase polyprotein 1abtarget
RemdesivirRNA-directed RNA polymerase Ltarget
RemdesivirCytochrome P450 2C8enzyme
RemdesivirCytochrome P450 2D6enzyme
RemdesivirCytochrome P450 3A4enzyme
RemdesivirSolute carrier organic anion transporter family member 1B1transporter
RemdesivirP-glycoprotein 1transporter
RemdesivirSolute carrier organic anion transporter family member 1B3transporter
RemdesivirBile salt export pumptransporter
RemdesivirMultidrug resistance-associated protein 4transporter
RemdesivirSodium/bile acid cotransportertransporter
RemdesivirLiver carboxylesterase 1enzyme
RemdesivirLysosomal protective proteinenzyme
RemdesivirReplicase polyprotein 1abtarget
RemdesivirReplicase polyprotein 1abtarget
RemdesivirMultidrug and toxin extrusion protein 1transporter
RegdanvimabSpike glycoproteintarget
CasirivimabSpike glycoproteintarget
ImdevimabSpike glycoproteintarget
BebtelovimabSpike glycoproteintarget